SCHEMBL721553

SCHEMBL721553

CCC(=O)OCc1ccc(F)cc1F

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.52
IDO1 P14902 2/20 0.51
AGXT P21549 2/20 0.51
ALDH1A1 P00352 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
GSK3B P49841 2/20 0.45
BACE1 P56817 2/20 0.45
RIPK1 Q13546 2/20 0.44
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGER1 P34995 1/20 0.40
MAPT P10636 2/20 0.40
POLB P06746 2/20 0.40
RAB9A P51151 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
PKM P14618 1/20 0.39
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3720430 0.87 MAOB (0.50) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL13034123 0.83 MAOB (0.59) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL6668911 0.82 IDO1 (0.58) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL14162423 0.81 MAOB (0.54) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL28819331 0.81 MMP2 (0.47) ALDH1A1KDM4EHPGDNPSR1HSD17B10
SCHEMBL14134236 0.80 RIPK1 (0.58) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL18100051 0.80 MAOB (0.49) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL27564590 0.79 ALDH1A1 (0.55) MAOBIDO1ALDH1A1TDP1KDM4E
SCHEMBL13544370 0.79 MAOB (0.55) MAOBIDO1AGXTALDH1A1TDP1
SCHEMBL6664565 0.78 MAOB (0.57) MAOBIDO1AGXTALDH1A1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759318-B2 Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections INHIBITEX, INC. (US) 2014-06-24 US disclosed
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) 2012-03-01 US disclosed
EP-2385951-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS University College Cardiff Consultants, Ltd. (GB) 2011-11-16 EP disclosed
US-20110254856-A1 MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL LG ELECTRONICS INC. (KR) 2011-10-20 US disclosed
WO-2010081082-A2 PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052046-A1 Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections PNP, SAMHD1, MTAP MAOB 3783/4885IDO1 3570/4885AGXT 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.